Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domperidone TQT Study in Healthy Chinese Subjects
NCT02816853Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of domperidone in nausea ((none)) and Vomiting (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change From Baseline in QTc Interval Based on Fridericia Correction Method at Day 4. Started May 2016; status: completed.
02
Drugs
domperidone
03
Conditions
nausea ((none))Vomiting
Beyond the preview
Go deeper on NCT02816853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02816853.